Chamber Cardio, a value-based cardiology company, announced Wednesday that it raised $60 million in Series A funding, which will be used to help scale the startup.
The company works with payers and cardiologists to support value-based care programs. Its platform uses AI inside clinicians’ existing workflows to flag high-risk patients, spot care gaps and reduce manual work. This helps improve outcomes and lowers hospital use, and it gives payers clearer insight into cardiovascular costs and performance.
“Chamber is focused on bringing value-based care to cardiology, the single largest driver of mortality and cost in the U.S.,” said George Aloth, Chamber’s co-founder and CEO, in an email. “We help cardiologists operate in a value-based world and scale their impact to become population health leaders in their communities.”
The Series A round was led by Frist Cressey Ventures, with participation from General Catalyst, AlleyCorp, American Family Ventures, Company Ventures, Optum Ventures, Healthworx Ventures and Black Opal Ventures. The funding also includes debt from HSBC Innovation Banking. In total, Chamber has raised $69.5 million.
“Cardiovascular disease is the largest driver of U.S. healthcare spend, yet care delivery remains fragmented and fee-for-service–driven. The Chamber platform brings value-based care to cardiology, delivering better outcomes and improved quality of life for patients and their families,” said Senator Bill Frist, MD, co-founder and managing partner at Frist Cressey Ventures, in a statement.
According to Aloth, the financing will be used in three ways: accelerating growth into new markets, expanding its care team and investing in technology to expand the use of AI. It currently has a network of more than 500 cardiologists across seven states.
Chamber’s announcement comes as heart disease is the leading cause of death in the U.S. for men, women and most racial and ethnic groups, according to the CDC. One person dies every 34 seconds from cardiovascular disease. In addition, the cost of healthcare services and medications for heart disease topped $168 billion between 2021 and 2022.
This is what Chamber aims to change. The company ultimately hopes to scale to as many cardiologists and patients as possible, Aloth said.
“We’re excited to partner with even more payers in both existing and new markets, giving more patients access to high-quality cardiovascular care at trusted local practices,” he said. “We’re also excited to push AI adoption across our network, as we think there’s huge potential for AI to expand the reach of cardiologists and improve outcomes for patients.”
Other value-based cardiology companies include Karoo Health and Novocardia.
Photo: Kmatta, Getty Images
